Compare RPGL & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RPGL | INM |
|---|---|---|
| Founded | 2015 | 1981 |
| Country | Singapore | Canada |
| Employees | 8 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3M | 2.1M |
| IPO Year | N/A | 2020 |
| Metric | RPGL | INM |
|---|---|---|
| Price | $2.05 | $1.78 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 653.1K | ★ 742.0K |
| Earning Date | 05-16-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,942,633.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.40 | ★ N/A |
| Revenue Growth | N/A | ★ 7.50 |
| 52 Week Low | $0.21 | $0.58 |
| 52 Week High | $13.06 | $2.71 |
| Indicator | RPGL | INM |
|---|---|---|
| Relative Strength Index (RSI) | 48.74 | 61.72 |
| Support Level | $1.90 | $1.49 |
| Resistance Level | $2.65 | $1.95 |
| Average True Range (ATR) | 0.22 | 0.15 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 36.73 | 29.76 |
Republic Power Group Ltd is a provider of customized ERP software solutions, consulting and technical support services, and peripheral hardware to corporate clients and government agencies, including airports, cruise terminals, and technology, trading, and logistics companies. The Company operates from Singapore and has historically served clients in Singapore and Malaysia, offering ERP systems with functions such as accounting, procurement, workflow automation, real-time monitoring, and capabilities including planning, surveillance, and threat detection. The Company leverages artificial intelligence and modular algorithms to address complex operational requirements and integrates sensors, controls, and other hardware to enable IoT connectivity with autonomous or semiautonomous outcomes.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.